This milestone reinforces Eccogenes position as an innovator in advancing novel, differentiated oral therapies for cardiometabolic diseases with broad commercial potential. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, commented: The start of this Phase 1b trial in China marks an important milestone in the extensive clinical program for AZD5004/ECC5004, an oral small molecule GLP-1RA which has significant potential as part of our extensive CVRM portfolio
We would also like to acknowledge all our collaborators for their contributions to our research, particularly Professor Angela C Roberts, Professor Edward T Bullmore, Alexander G
Adults meeting the studys obesity criteria, who newly initiated tirzepatide or semaglutide, were identified and compared with matched individuals who started naltrexone-bupropion, phentermine, or phentermine-topiramate
Sermorelin was studied over six weeks in 11 elderly males receiving 2mg/daily as subcutaneous injections
Consider creatine